The private equity firm’s latest fund has closed with $2.1bn from backers including endowments for specialty materials, chemicals and pharmaceuticals investments.
SK Capital Partners, a US-based private equity firm focused on speciality materials, chemicals and pharmaceuticals, has secured commitments of $2.1bn from investors including unnamed endowments for the final close of its fifth fund.
None of SK Capital Partners Fund V’s limited partners have been named, however the consortium includes public pension funds, insurers, sovereign wealth funds, family offices and fund-of-funds.
The vehicle includes an overage side fund allotted to offer faster investments and greater certainty to potential investees…
